ezetimibe has been researched along with Depressive Disorder in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colivicchi, F; Di Fusco, SA; Macchiusi, A; Spinelli, A | 1 |
| Alfadhel, M; Alghamdi, F; Alghamdi, J; Alghamdi, S; Matou-Nasri, S; Padmanabhan, S | 1 |
2 other study(ies) available for ezetimibe and Depressive Disorder
| Article | Year |
|---|---|
[Importance of the individualized care process in a patient with recurrent acute coronary syndrome, multiple comorbidities and depressive syndrome].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cholesterol, LDL; Depressive Disorder; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium | 2022 |
Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.
Topics: Depressive Disorder; Ezetimibe; Genome-Wide Association Study; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Membrane Proteins; Membrane Transport Proteins; Mendelian Randomization Analysis; Neurotic Disorders; PCSK9 Inhibitors; Polymorphism, Single Nucleotide; Proprotein Convertase 9; Sleep Initiation and Maintenance Disorders | 2018 |